Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317848 | 1.00 | EPHX2 (0.47) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1317851 | 1.00 | EPHX2 (0.47) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1317877 | 0.88 | EPHX2 (0.49) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1317797 | 0.88 | EPHX2 (0.43) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1317792 | 0.88 | EPHX2 (0.43) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1317794 | 0.88 | EPHX2 (0.43) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1317256 | 0.87 | POLB (0.41) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1317258 | 0.87 | POLB (0.41) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1319051 | 0.83 | EPHX2 (0.48) | EPHX2LMNAHTTSMN1; SMN2POLB | |
| SCHEMBL1319582 | 0.83 | EPHX2 (0.48) | EPHX2LMNAHTTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | EPHX2 4071/4885LMNA 4686/4885HTT 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.